Niagen Bioscience, Inc. (NAGE)

Niagen Bioscience Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	64.79	44.66	27.33	20.44	28.22
Cash & Short-Term Investments	64.79	44.66	27.33	20.44	28.22
Cash Growth	45.07%	63.44%	33.68%	-27.56%	69.01%
Accounts Receivable	9.74	7.77	5.23	8.48	5.23
Inventory	20.42	9.19	14.53	14.68	13.6
Other Current Assets	1.85	2.48	2.45	2.97	1.86
Total Current Assets	96.81	64.1	49.53	46.57	48.91
Net Property, Plant & Equipment	3.52	3.45	4.54	6.32	7.36
Other Intangible Assets	5.66	0.36	0.51	0.67	0.86
Other Long-Term Assets	0.43	0.37	0.38	0.5	0.72
Total Assets	106.41	68.28	54.96	54.06	57.84
Accounts Payable	10.8	8.53	10.23	9.68	10.42
Accrued Expenses	7.72	7.82	9.49	7.34	6.48
Current Portion of Leases	1	0.99	0.7	0.7	0.55
Unearned Revenue	0.4	0.61	0.2	0.16	0.16
Total Current Liabilities	19.92	17.95	20.62	17.87	17.61
Long-Term Leases	1.82	1.66	2.58	3.56	4.15
Other Long-Term Liabilities	8.14	2.58	3.31	3.96	4.35
Total Long-Term Liabilities	9.95	4.24	5.89	7.52	8.5
Total Liabilities	29.87	22.18	26.51	25.39	26.11
Common Stock	-	0.08	0.08	0.07	0.07
Additional Paid-in Capital	-	227.93	218.85	214.09	200.61
Accumulated Other Comprehensive Income	-	-0	-0	-0	-0
Retained Earnings	-	-181.91	-190.46	-185.49	-168.95
Shareholders' Equity	76.53	46.09	28.46	28.67	31.73
Total Liabilities & Equity	106.41	68.28	54.96	54.06	57.84
Total Debt	2.82	2.65	3.28	4.26	4.7
Net Cash (Debt)	61.97	42.01	24.05	16.18	23.52
Net Cash Growth	47.52%	74.69%	48.59%	-31.18%	56.16%
Net Cash Per Share	0.72	0.54	0.32	0.23	0.35
Book Value	76.53	46.09	28.46	28.67	31.73
Book Value Per Share	0.90	0.59	0.38	0.41	0.47
Tangible Book Value	70.87	45.74	27.95	28	30.87
Tangible Book Value Per Share	0.83	0.59	0.37	0.40	0.46

Updated Mar 4, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q